Inhibrx Biosciences, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDInhibrx Biosciences, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings growth of 36% provides fundamental context to the price action. However, with RSI at 75, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $107.00 | +32.56% | ABOVE |
| 50 SMA | $83.90 | +69.07% | ABOVE |
| 100 SMA | $81.24 | +74.59% | ABOVE |
| 150 SMA | $75.65 | +87.48% | ABOVE |
| 200 SMA | $63.18 | +124.51% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is INBX in an uptrend right now?
INBX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, INBX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is INBX overbought or oversold?
INBX's RSI (14) is 75. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is INBX outperforming the market?
INBX has a Relative Strength (RS) Rating of 97 out of 99. Yes, INBX is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is INBX in its 52-week range?
INBX is trading at $141.84, which is 91% of its 52-week high ($155.29) and 91% above its 52-week low ($10.84).
How volatile is INBX?
INBX has a Beta of 1.79 and 52-week volatility of 78%. It's more volatile than the S&P 500 - expect bigger swings.